Author

admin

Browsing

Demetre Daskalakis, an official at the Centers for Disease Control and Prevention (CDC), resigned this week, claiming the Trump administration’s policies ignore science. However, his own leadership during the Biden-era monkeypox response was criticized for putting optics over public health.

Amid the Trump administration’s efforts to push out CDC Director Susan Monarez, a handful of other top CDC officials, including Daskalakis, resigned in protest of the Trump administration’s policies. Daskalakis wrote in his resignation letter that was posted to social media that the health policies put forward by Secretary Robert F. Kennedy do not ‘reflect scientific reality.’ He also accused the Trump administration of attempting to ‘erase transgender populations,’ while also using the term ‘pregnant people’ to describe women who are about to give birth.

But flashback to 2022 and 2023, after the monkeypox virus had spread across several countries and made its way into the U.S., during which Daskalakis was among the Biden administration’s top advisers who spearheaded the national response to the disease outbreak. 

Government communications from that time period, uncovered by watchdog group the Oversight Project, show that officials were aware that the disease was spreading among the gay community. However, those communications, and other records, show the administration appeared to be more concerned with protecting the stigma targeting the gay community, than they were with implementing measures that would provide the best mitigation response.

‘A common theme was public health officials identifying locations where outbreaks occurred, to include bathhouses and saunas,’ according to the Oversight Project. ‘Officials never broached consideration of shutting down these locations. This draws a stark contrast to the public health guidance and shutdowns of gathering places during COVID, to include gyms and skate parks.’

In 2023, after the monkeypox outbreak had taken hold in the U.S., Daskalakis went on national television to let the country know that his team was ‘making sure [they] got the word out in a way that supports people’s joy, as opposed to calling them risky.’

‘You know, one person’s idea of risk, is another person’s idea of a great festival or Friday night, for that matter. So, we have to sort of embrace that with joy and make sure that folks know how to keep themselves safe,’ the Biden monkeypox coordinator added.

 

Meanwhile, during the outbreak, Daskalkis posted a tweet from gay sex app Grindr that stated ‘Dr. Daskalakis could jab me any day,’ with a sticker of a flattered cat.

In other social media posts from around the same time, Daskalkis can be seen using male models wearing leather bondage straps to make an entrance at an HIV prevention summit. 

While in his role at the White House leading the monkeypox response, Daskalkis also reportedly ran an STD screening operation from an after-hours sex club in New York City. When asked about the operation in an interview, Daskalakis described it as ‘exciting’ and added there was ‘not much sleep time.’ Later in the interview, he added: ‘I’d already kind of been the bathhouse HIV testing doctor.’

Fox News Digital reached out to Daskalakis about the juxtaposition between his criticism of Kennedy’s policies not reflecting ‘scientific reality,’ and his role in the Biden administration’s approach to monkeypox, but did not receive an immediate response.

This post appeared first on FOX NEWS

Spirit Airlines on Friday filed for bankruptcy protection, just months after the budget carrier failed to secure better financial footing when it came out of Chapter 11 protection in March.

The Dania Beach, Florida-based airline said under this bankruptcy, it will reduce its network and shrink its fleet, cuts that it said will reduce costs by “hundreds of millions of dollars” a year.

In a release, Spirit said guests can continue to book, travel and use tickets, credits and loyalty points. Wages and benefits will continue to be paid and honored, including contractors, it said. Spirit intends to pay vendors and suppliers for goods and services provided on or after the filing date in the ordinary course.

“Since emerging from our previous restructuring, which was targeted exclusively on reducing Spirit’s funded debt and raising equity capital, it has become clear that there is much more work to be done and many more tools are available to best position Spirit for the future,” Spirit CEO Dave Davis said in a news release on Friday.

Spirit had just gotten out of bankruptcy in March after four months, only to be dragged down by continued high costs and weaker U.S. domestic demand. The carrier had struggled for years as it dealt with a glut of U.S. flights, a Pratt & Whitney engine recall and a failed takeover by JetBlue Airways, a deal that was blocked in court.

Firms that used Spirit’s aircrafts had reached out to rival airlines in recent weeks to gauge executives’ interest in some of the carrier’s planes, according to people familiar with the matter.

Spirit is the United States’ largest budget airline, followed closely by rival Frontier Airlines which has tried and failed to merge with Spirit repeatedly since 2022. Frontier on Tuesday announced 20 new routes that compete with Spirit to win over its struggling competitor’s customers.

This post appeared first on NBC NEWS

Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on through generations. So what is genetics investing?

When it comes to genetics investing, companies in this niche of the life science sector are mostly focused on four submarkets: DNA sequencing, genetic testing, gene therapy and genomics, which includes gene editing.

This life sciences submarket has gained much attention from investors over the past several years. It has provided a launching pad for a number of biotech firms developing and commercializing novel treatments and drugs addressing a wide range of diseases with unmet needs.

For those looking to dive into the genetics sector, there are numerous investment opportunities to consider. Investing in gene stocks is the most common route, but there are risks due to the market’s volatility, especially when it comes to wins or losses with the US Food and Drug Administration (FDA).

Exchange-traded funds (ETFs) are another popular option for gaining exposure to the industry, and come with less risk than investing in a single stock.

In this article

    What are the key areas of the genetics sector?

    Before diving into investment opportunities in the genetics market, it’s important to understand the industry and the key areas of genetics mentioned above.

      What investors should know about the genetics market

      In the biotech sector, gene therapy is one of the more advanced treatment options, and gene therapy pipeline candidates are robust in late-stage clinical trials.

      In terms of what will — and already has — disrupted the genetics industry, CRISPR gene-editing technology has been on the rise for quite some time. It uses short repeating DNA sequences with “spacers” dividing them to treat genetic diseases.

      While the use of the technology is still in its early stages, in the coming years it’s expected to have a big impact on how genetic diseases are treated, and there are a range of clinical trials underway involving CRISPR technology. So far, the only FDA approved CRISPR-based medicine is Casgevy, developed by Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP). It was originally approved in late 2023 for the treatment of sickle cell disease.

      The prominence of gene therapies in the life science sector was a major theme at the 2025 JPMorgan Healthcare Conference in January 2025. Peter Marks, then-director of the FDA’s Center for Biological Evaluation and Research, told attendees that his agency is aiming to accelerate approvals for gene therapies.

      In 2024, the FDA expanded approvals for CRISPR-based Casgevy to beta-thalassemia, and it also approved Pfizer’s (NYSE:PFE) Beqvez and PTC Therapeutics’ (NASDAQ:PTC) Kebilidi.

      Despite experiencing a challenging year in 2024, there is still a lot of optimism in the gene therapy sector. Also speaking at the January conference, Alliance for Regenerative Medicine president Tim Hunt said he believes 10 new cell and gene therapy treatments could reach blockbuster status by 2030.

      “No one’s saying there aren’t headwinds, but we are seeing important signs of growth,” he added.

      Looking at DNA sequencing, this market is driven by advances in biotech, the increasing prevalence of cancer and rising demand for precision medicine, as well as higher investment in research and development. DNA sequencing has become a vital component of this growth and has played a key role in remodeling molecular biology and genomics research.

      Genetic testing is another segment of the genetics industry that is growing at a fast pace. Unsurprisingly, technological breakthroughs have had a huge impact on genetic testing, and so has the fact that governments and regulatory bodies are turning their attention to this market in order to regulate and raise awareness to treat diseases such as cancer, cystic fibrosis and sickle cell anemia.

      Biotech and pharmaceutical companies are also expressing interest in this sector, which is expected to further fuel genetics sector growth in the coming years. Mergers and acquisitions activity is also expected to increase as companies seek to expand their product portfolios new candidates and technologies.

      As can be seen, the genetics industry is vast and complex, but is also ripe with investment opportunities.

      How to invest in gene stocks

      Investors looking to invest in the field of genetics through stocks have many options, from large-cap biotech companies to pure-play gene therapy, gene editing and genetic testing stocks.

      See the list below for genetics companies to consider, and check out the linked stock lists for more options.

      Large-cap gene stocks

      There are a number of large-cap biotech companies that have significant focuses on the field of genomics. Here are a few to consider:

      Amgen (NASDAQ:AMGN)
      A global leader in biotech, Amgen uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs. The company’s subsidiary deCODE Genetics is researching how human genetic diversity influences disease.

      AbbVie (NYSE:ABBV)
      Research-based global biopharmaceutical company AbbVie that addresses several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology. AbbVie is collaborating with ADARx Pharmaceuticals to develop siRNA therapeutics, viewed as a promising genetic medicine approach for silencing disease-causing genes.

      Regeneron Pharmaceuticals (NASDAQ:REGN)
      Regeneron Pharmaceuticals creates medicines for a wide variety of diseases. The Regeneron Genetics Center is conducting one of the world’s largest genetics sequencing efforts in collaboration with health organizations around the world.

      Gene editing (CRISPR) stocks

      There are a variety of options for investors looking to buy in on the field of gene editing stocks, including:

      CRISPR Therapeutics (NASDAQ:CRSP)
      CRISPR Therapeutics and its partner Vertex Pharmaceuticals co-developed drug Casgevy, a CRISPR/Cas9 genome-edited cell therapy. Casgevy is the first ever treatment based on CRISPR technology to be approved for the US market, as well as by the European Medicines Agency and Health Canada.

      Intellia Therapeutics (NASDAQ:NTLA)
      Intellia Therapeutics is a gene editing biotech company developing drugs for patients with genetic and autoimmune diseases. The company’s drug pipeline includes late-stage clinical programs for therapies targeting hereditary angioedema and transthyretin amyloidosis.

      Vertex Pharmaceuticals (NASDAQ:VRTX)
      Vertex Pharmaceuticals is the other half of the team behind Casgevy. It also offers exposure to other sectors of genomics, with approved treatments for cystic fibrosis and a pipeline of genetic and cell therapies. Its investigational VX-880 islet cell replacement therapy could restore insulin production in patients with type 1 diabetes.

      Gene therapy stocks

      Gene therapy stocks and stem cell stocks are also popular choices for genetics investing. Here are a few to get you started:

      Novartis (NYSE:NVS)
      Switzerland-based Novartis is focused on treatments for a wide range of diseases, including cancers, malaria, leprosy and sickle cell disease. Novartis is developing adeno-associated-virus (AAV)-based and CRISPR-based gene therapies. Its Kymriah treatment was the first CAR-T cell therapy to be approved by the FDA, and the agency also approved its AAV-based therapy Zolgensma.

      Gilead Sciences (NASDAQ:GILD)
      Global biopharmaceutical company Gilead Sciences is advancing breakthrough medicines to prevent and treat serious diseases such as HIV, viral hepatitis and cancer. Its cell-based gene medicine for blood cancer, the CAR T-cell therapy Yescarta, was the second gene therapy approved by FDA.

      uniQure (NASDAQ:QURE)
      Genomic medicine company uniQure develops and markets gene therapy products for patients with severe genetic diseases. The company’s AAV-based gene therapy platform targets liver-directed and central nervous system disorders.

      Genetic testing stocks

      For those interested in genetic testing stocks, these three stocks provide a snapshot on different ways to get exposure to the sector:

      Exact Sciences (NASDAQ:EXAS)
      Exact Sciences focuses on molecular diagnostic tests. The company has developed a molecular screening technology platform called Cologuard that detects a range of cancers, including breast cancer and colorectal cancer.

      Fulgent Genetics (NASDAQ:FLGT)
      A leader in clinical diagnostic genetic sequencing, Fulgent Genetics is a full-service genomics testing company. Its proprietary technology platform, Picture Genetics, allows for the identification of personal DNA health markers in individual patients.

      Illumina (NASDAQ:ILMN)
      Illumina develops, manufactures and markets life science tools and integrated systems that enable the implementation of genomic solutions for the healthcare sector. Its focus is on oncology testing, genetic disease testing, reproductive health and research.

      How to invest in genomics ETFs

      For those who would prefer to invest in the genetics industry overall rather than buying shares in an individual gene stock, investing in genomics ETFs is the way to go. Here are some available ETFs that offer exposure to companies in the biotech and genetics sectors to start you off:

      ARK Genomic Revolution ETF (ARCA:ARKG)
      This ETF tracks firms focused on CRISPR technology, targeted therapeutics, bioinformatics, molecular diagnostics, stem cells and agricultural biology. Its holdings include CRISPR Therapeutics and Guardant Health (NASDAQ:GH).

      Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)
      The Global X Genomics & Biotechnology ETF invests in stocks that are involved in genomic science, which includes gene computational genomics and biotechnology. Its holdings include Illumina and Avidity Biosciences (NASDAQ:RNA).

      iShares Genomics Immunology and Healthcare ETF (ARCA:IDNA)
      The iShares Genomics Immunology and Healthcare ETF focuses on companies involved with genomics, immunology and bioengineering. Its holdings include Regeneron Pharmaceuticals and Arcellx (NASDAQ:ACLX).

      Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

      This post appeared first on investingnews.com

      Bipartisan anger is brewing over the drama that unfolded at the Centers for Disease Control (CDC), with the top members of the Senate’s healthcare panel forming a united front in the midst of the turmoil.

      Senate Healthcare, Education, Labor and Pensions Committee Chair Bill Cassidy, R-La., and the panel’s ranking member, Sen. Bernie Sanders, I-Vt., dove head first into the issues stemming from the firing of CDC Director Susan Monarez, which spurred a string of departures from the agency.

      Monarez was abruptly fired from her position by the Department of Health and Human Services (HHS), less than a month after being confirmed by the Senate. Her removal, which her lawyers rejected, appeared to stem from disagreements over vaccines with HHS Secretary Robert F. Kennedy, Jr., a vaccine skeptic.

      Cassidy was the deciding vote during Kennedy’s confirmation hearing earlier this year.

      Monarez has since refused to leave the post, with her lawyers arguing that she had neither resigned nor been fired and had not received notification from the president of her removal.

      Following news of her ouster, a string of top officials at the CDC announced their resignations, too, including National Center for Emerging and Zoonotic Infectious Diseases Director Dr. Daniel Jernigan, Chief Medical Officer Debra Houry, National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis and Director of Public Health Data, Science, Technology Jennifer Layden.

      In response to their resignations, Cassidy demanded that the federal government’s vaccine advisory panel, which was filled with Kennedy’s handpicked replacements after he recently booted the original panel members, postpone its scheduled meeting in September.

      His demand marks the second time this year that Cassidy called on the panel to halt its meeting, a move that directly bucks Kennedy’s and President Donald Trump’s Make America Healthy Again (MAHA) agenda. 

      Cassidy argued Thursday that there were ‘serious allegations made about the meeting agenda, membership, and lack of scientific process being followed for the now announced September [Advisory Committee on Immunization Practices] meeting.’

      ‘These decisions directly impact children’s health, and the meeting should not occur until significant oversight has been conducted,’ Cassidy said. ‘If the meeting proceeds, any recommendations made should be rejected as lacking legitimacy given the seriousness of the allegations and the current turmoil in CDC leadership.’

      Daskalakis posted his reason for resigning on X, where he charged that he was ‘unable to serve in an environment that treats CDC as a tool to generate policies and materials that do not reflect scientific reality and are designed to hurt rather than to improve the public’s health.’

      Meanwhile, Sanders demanded a congressional investigation be opened into the Trump administration’s decision to fire Monarez.

      ‘We need leaders at the CDC and HHS who are committed to improving public health and have the courage to stand up for science, not officials who have a history of spreading bogus conspiracy theories and disinformation,’ Sanders said Thursday.

      HHS did not immediately respond to a request for comment for this story.  

      This post appeared first on FOX NEWS

      A spokesperson for Kamala Harris confirmed to Fox News on Friday that the former vice president’s Secret Service protection has been revoked by President Donald Trump.

      The spokesperson added that there was no reason given as to why it was removed.

      A senior White House official told Fox News Digital that vice presidents usually have a Secret Service detail for only six months after departing office.

      A source briefed on the matter also told Fox News that the decision to revoke Harris’ Secret Service protection was made yesterday and that is when the Secret Service was notified.

      Former President Joe Biden signed an executive memorandum before leaving office which extended Harris’ protection for an additional year after the normal six months that former vice presidents received in the past.

      On Thursday, Trump rescinded that memorandum and Harris’ Secret Service protection officially ends on Sept. 1.

      The move comes as Harris is set to kick off a tour for her upcoming book ‘107 Days’ in late September.

      The tour is scheduled to visit major American cities in its opening days, including New York City, Philadelphia and Los Angeles.

      This is a developing story. Please check back for updates.

      This post appeared first on FOX NEWS

      A Centers for Disease Control and Prevention official who posted his resignation letter on social media used the term ‘pregnant people’ and capped off his missive by including ‘he/his/him’ pronouns after his name.

      ‘I am writing to formally resign from my position as Director of the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC), effective August 28, 2025, close of business,’ Dr. Demetre Daskalakis wrote in the lengthy post on X.

      Daskalakis accused President Donald Trump’s administration of attempting ‘to erase transgender populations.’

      ‘For decades, I have been a trusted voice for the LGBTQ community when it comes to critical health topics. I must also cite the recklessness of the administration in their efforts to erase transgender populations, cease critical domestic and international HIV programming, and terminate key research to support equity as part of my decision,’ he wrote.

      The inclusion of pronouns and the term ‘pregnant people’ caught people’s attention.

      ‘This resignation is a huge win for the Trump administration and the American people. We don’t need anyone who can’t understand basic biology working at the CDC,’ noted Jeremy Redfern, communications director for Florida Attorney General James Uthmeier.

      Karol Markowicz tweeted, ‘No one who uses ‘pregnant people’ should work at the CDC. This isn’t hard.’ 

      Responding to Markowicz’s post, Florida Gov. Ron DeSantis wrote, ‘Example of how ‘trusting the science’ really means following the political science and perpetuating the prevailing narrative…’ He added, ‘Embracing evidence-based medicine should be the bare minimum for working at the CDC…’

      Daskalakis suggested that the Department of Health and Human Services is on a ‘dangerous’ path.

      ‘I am unable to serve in an environment that treats CDC as a tool to generate policies and materials that do not reflect scientific reality and are designed to hurt rather than to improve the public’s health,’ he wrote.

      ‘I wish the CDC continued success in its vital mission and that HHS reverse its dangerous course to dismantle public health as a practice and as an institution. If they continue the current path, they risk our personal well-being and the security of the United States,’ Daskalakis concluded at the end of his message.

      Fox News Digital reached out to HHS for comment on Thursday.

      This post appeared first on FOX NEWS